Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye

NCT02326090 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

161

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye Syndrome

Interventions

DRUG: cis-UCA ophthalmic solution 1.0%
DRUG: cis-UCA ophthalmic solution 2.5%
DRUG: Placebo ophthalmic solution

Sponsor

Herantis Pharma Plc.

Collaborators

[object Object]